The Role of Oxidative Stress in Neurodegenerative Diseases

Experimental Neurobiology

Volumn 24, Issue 4, 2015, Pages 325-340

  Kim, Geon Ha ^a,b   Kim, Jieun E ^a   Rhie, Sandy Jeong ^a   Yoon, Sujung ^a  

^a Ewha Womans University   (South Korea)

^b Mokdong Hospital   (South Korea)

Author keywords

Alzheimer s disease; Antioxidant; Neurodegenerative disease; Oxidative stress; Parkinson s disease; Reactive oxygen species

Indexed keywords

EID: 84978864589     PISSN: 12262560     EISSN: 20938144     Source Type: Journal    
DOI: 10.5607/en.2015.24.4.325     Document Type: Review

References (140)

1. Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443: 787-795.
2. Gandhi S, Abramov AY (2012) Mechanism of oxidative stress in neurodegeneration. Oxid Med Cell Longev 2012:428010.
3. Song P, Zou MH (2015) Roles of reactive oxygen species in physiology and pathology. In: Atherosclerosis: risks, mechanisms, and therapies (Wang H, Patterson C, eds), pp 379-392. John Wiley & Sons Inc., Hoboken, NJ.
4. Federico A, Cardaioli E, Da Pozzo P, Formichi P, Gallus GN, Radi E (2012) Mitochondria, oxidative stress and neurodegeneration. J Neurol Sci 322:254-262.
5. Patten DA, Germain M, Kelly MA, Slack RS (2010) Reactive oxygen species: stuck in the middle of neurodegeneration. J Alzheimers Dis 20 Suppl 2:S357-S367.
6. Held P (2012) An introduction to reactive oxygen species: measurement of ROS in cells (white paper). BioTek Instruments, Inc., Winooski, VT.
7. Bolisetty S, Jaimes EA (2013) Mitochondria and reactive oxygen species: physiology and pathophysiology. Int J Mol Sci 14:6306-6344.
8. Halliwell B (2006) Oxidative stress and neurodegeneration: where are we now? J Neurochem 97:1634-1658.
9. Zorov DB, Juhaszova M, Sollott SJ (2014) Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol Rev 94:909-950.
10. Mani S (2015) Production of reactive oxygen species and its implication in human diseases. In: Free radicals in human health and disease (Rani V, Yadav UC, eds), pp 3-15. Springer, New Delhi.
11. Orrenius S (2007) Reactive oxygen species in mitochondria-mediated cell death. Drug Metab Rev 39:443-455.
12. Widlansky ME, Gutterman DD (2011) Regulation of endothelial function by mitochondrial reactive oxygen species. Antioxid Redox Signal 15:1517-1530.
13. Cadenas E, Davies KJ (2000) Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med 29:222-230.
14. Mancuso M, Coppede F, Migliore L, Siciliano G, Murri L (2006) Mitochondrial dysfunction, oxidative stress and neurodegeneration. J Alzheimers Dis 10:59-73.
15. Quinlan CL, Perevoshchikova IV, Hey-Mogensen M, Orr AL, Brand MD (2013) Sites of reactive oxygen species generation by mitochondria oxidizing different substrates. Redox Biol 1:304-312.
16. McLennan HR, Degli Esposti M (2000) The contribution of mitochondrial respiratory complexes to the production of reactive oxygen species. J Bioenerg Biomembr 32:153-162.
17. Yankovskaya V, Horsefield R, Törnroth S, Luna-Chavez C, Miyoshi H, Léger C, Byrne B, Cecchini G, Iwata S (2003) Architecture of succinate dehydrogenase and reactive oxygen species generation. Science 299:700-704.
18. Turrens JF (2003) Mitochondrial formation of reactive oxygen species. J Physiol 552:335-344.
19. Infanger DW, Sharma RV, Davisson RL (2006) NADPH oxidases of the brain: distribution, regulation, and function. Antioxid Redox Signal 8:1583-1596.
20. Babior BM (2004) NADPH oxidase. Curr Opin Immunol 16: 42-47.
21. Lambeth JD (2004) NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 4:181-189.
22. Song P, Zou MH (2012) Regulation of NAD(P)H oxidases by AMPK in cardiovascular systems. Free Radic Biol Med 52: 1607-1619.
23. Görlach A, Brandes RP, Nguyen K, Amidi M, Dehghani F, Busse R (2000) A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circ Res 87:26-32.
24. Bengtsson SH, Gulluyan LM, Dusting GJ, Drummond GR (2003) Novel isoforms of NADPH oxidase in vascular physiology and pathophysiology. Clin Exp Pharmacol Physiol 30:849-854.
25. Wingler K, Wönsch S, Kreutz R, Rothermund L, Paul M, Schmidt HH (2001) Upregulation of the vascular NAD(P) H-oxidase isoforms Nox1 and Nox4 by the renin-Angiotensin system in vitro and in vivo. Free Radic Biol Med 31:1456-1464.
26. Van Buul JD, Fernandez-Borja M, Anthony EC, Hordijk PL (2005) Expression and localization of NOX2 and NOX4 in primary human endothelial cells. Antioxid Redox Signal 7: 308-317.
27. Clempus RE, Sorescu D, Dikalova AE, Pounkova L, Jo P, Sorescu GP, Schmidt HH, Lassègue B, Griendling KK (2007) Nox4 is required for maintenance of the differentiated vascular smooth muscle cell phenotype. Arterioscler Thromb Vasc Biol 27:42-48.
28. Ellmark SH, Dusting GJ, Fui MN, Guzzo-Pernell N, Drummond GR (2005) The contribution of Nox4 to NADPH oxidase activity in mouse vascular smooth muscle. Cardiovasc Res 65:495-504.
29. Bedard K, Krause KH (2007) The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87:245-313.
30. Gordillo G, Fang H, Park H, Roy S (2010) Nox-4-dependent nuclear H2O2 drives DNA oxidation resulting in 8-OHdG as urinary biomarker and hemangioendothelioma formation. Antioxid Redox Signal 12:933-943.
31. Dikalov SI, Dikalova AE, Bikineyeva AT, Schmidt HH, Harrison DG, Griendling KK (2008) Distinct roles of Nox1 and Nox4 in basal and angiotensin II-stimulated superoxide and hydrogen peroxide production. Free Radic Biol Med 45: 1340-1351.
32. Abramov AY, Scorziello A, Duchen MR (2007) Three distinct mechanisms generate oxygen free radicals in neurons and contribute to cell death during anoxia and reoxygenation. J Neurosci 27:1129-1138.
33. Dasuri K, Zhang L, Keller JN (2013) Oxidative stress, neurodegeneration, and the balance of protein degradation and protein synthesis. Free Radic Biol Med 62:170-185.
34. Harrison R (2002) Structure and function of xanthine oxidoreductase: where are we now? Free Radic Biol Med 33:774-797.
35. Harrison R (2004) Physiological roles of xanthine oxidoreductase. Drug Metab Rev 36:363-375.
36. Bhandary B, Marahatta A, Kim HR, Chae HJ (2012) An involvement of oxidative stress in endoplasmic reticulum stress and its associated diseases. Int J Mol Sci 14:434-456.
37. Higa A, Chevet E (2012) Redox signaling loops in the unfolded protein response. Cell Signal 24:1548-1555.
38. Malhotra JD, Kaufman RJ (2007) Endoplasmic reticulum stress and oxidative stress: A vicious cycle or a double-edged sword? Antioxid Redox Signal 9:2277-2294.
39. Schrader M, Fahimi HD (2006) Peroxisomes and oxidative stress. Biochim Biophys Acta 1763:1755-1766.
40. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J (2007) Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39:44-84.
41. Power JH, Blumbergs PC (2009) Cellular glutathione peroxidase in human brain: cellular distribution, and its potential role in the degradation of Lewy bodies in Parkinson's disease and dementia with Lewy bodies. Acta Neuropathol 117:63-73.
42. Brigelius-Flohé R, Maiorino M (2013) Glutathione peroxidases. Biochim Biophys Acta 1830:3289-3303.
43. Dröge W (2002) Free radicals in the physiological control of cell function. Physiol Rev 82:47-95.
44. Espinosa-Diez C, Miguel V, Mennerich D, Kietzmann T, Sánchez-Pérez P, Cadenas S, Lamas S (2015) Antioxidant responses and cellular adjustments to oxidative stress. Redox Biol 6:183-197.
45. Wood ZA, Schröder E, Robin Harris J, Poole LB (2003) Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci 28:32-40.
46. Oberley TD, Verwiebe E, Zhong W, Kang SW, Rhee SG (2001) Localization of the thioredoxin system in normal rat kidney. Free Radic Biol Med 30:412-424.
47. Seo MS, Kang SW, Kim K, Baines IC, Lee TH, Rhee SG (2000) Identification of a new type of mammalian peroxiredoxin that forms an intramolecular disulfide as a reaction intermediate. J Biol Chem 275:20346-20354.
48. Hall A, Nelson K, Poole LB, Karplus PA (2011) Structure-based insights into the catalytic power and conformational dexterity of peroxiredoxins. Antioxid Redox Signal 15:795-815.
49. Winterbourn CC, Metodiewa D (1994) The reaction of superoxide with reduced glutathione. Arch Biochem Biophys 314:284-290.
50. Winterbourn CC (2008) Reconciling the chemistry and biology of reactive oxygen species. Nat Chem Biol 4:278-286.
51. Marinho HS, Real C, Cyrne L, Soares H, Antunes F (2014) Hydrogen peroxide sensing, signaling and regulation of transcription factors. Redox Biol 2:535-562.
52. Lee M, Cho T, Jantaratnotai N, Wang YT, McGeer E, McGeer PL (2010) Depletion of GSH in glial cells induces neurotoxicity: relevance to aging and degenerative neurological diseases. FASEB J 24:2533-2545.
53. Dringen R, Gutterer JM, Hirrlinger J (2000) Glutathione metabolism in brain metabolic interaction between astrocytes and neurons in the defense against reactive oxygen species. Eur J Biochem 267:4912-4916.
54. Dringen R (2000) Metabolism and functions of glutathione in brain. Prog Neurobiol 62:649-671.
55. Dringen R, Hirrlinger J (2003) Glutathione pathways in the brain. Biol Chem 384:505-516.
56. Presnell CE, Bhatti G, Numan LS, Lerche M, Alkhateeb SK, Ghalib M, Shammaa M, Kavdia M (2013) Computational insights into the role of glutathione in oxidative stress. Curr Neurovasc Res 10:185-194.
57. Song J, Kang SM, Lee WT, Park KA, Lee KM, Lee JE (2014) Glutathione protects brain endothelial cells from hydrogen peroxide-induced oxidative stress by increasing nrf2 expression. Exp Neurobiol 23:93-103.
58. Groeger G, Quiney C, Cotter TG (2009) Hydrogen peroxide as a cell-survival signaling molecule. Antioxid Redox Signal 11:2655-2671.
59. Manea A (2010) NADPH oxidase-derived reactive oxygen species: involvement in vascular physiology and pathology. Cell Tissue Res 342:325-339.
60. Lassègue B, Griendling KK (2010) NADPH oxidases: functions and pathologies in the vasculature. Arterioscler Thromb Vasc Biol 30:653-661.
61. de Vries HE, Witte M, Hondius D, Rozemuller AJ, Drukarch B, Hoozemans J, van Horssen J (2008) Nrf2-induced antioxidant protection: A promising target to counteract ROS-mediated damage in neurodegenerative disease? Free Radic Biol Med 45:1375-1383.
62. Hybertson BM, Gao B, Bose SK, McCord JM (2011) Oxidative stress in health and disease: The therapeutic potential of Nrf2 activation. Mol Aspects Med 32:234-246.
63. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, Yamamoto M (1999) Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-Terminal Neh2 domain. Genes Dev 13:76-86.
64. Bubici C, Papa S, Dean K, Franzoso G (2006) Mutual cross-Talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance. Oncogene 25:6731-6748.
65. Kriete A, Mayo KL (2009) Atypical pathways of NF-kappaB activation and aging. Exp Gerontol 44:250-255.
66. Toledano MB, Leonard WJ (1991) Modulation of transcription factor NF-kappa B binding activity by oxidation-reduction in vitro. Proc Natl Acad Sci U S A 88:4328-4332.
67. Ray PD, Huang BW, Tsuji Y (2012) Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal 24:981-990.
68. Wang X, Michaelis EK (2010) Selective neuronal vulnerability to oxidative stress in the brain. Front Aging Neurosci 2:12.
69. Ferreira ME, de Vasconcelos AS, da Costa Vilhena T, da Silva TL, da Silva Barbosa A, Gomes AR, Dolabela MF, Percário S (2015) Oxidative Stress in Alzheimer's Disease: Should We Keep Trying Antioxidant Therapies? Cell Mol Neurobiol 35: 595-614.
70. Mattson MP (2004) Pathways towards and away from Alzheimer's disease. Nature 430:631-639.
71. Wang X, Wang W, Li L, Perry G, Lee HG, Zhu X (2014) Oxidative stress and mitochondrial dysfunction in Alzheimer's disease. Biochim Biophys Acta 1842:1240-1247.
72. Zhao Y, Zhao B (2013) Oxidative stress and the pathogenesis of Alzheimer's disease. Oxid Med Cell Longev 2013:316523.
73. Radi E, Formichi P, Battisti C, Federico A (2014) Apoptosis and oxidative stress in neurodegenerative diseases. J Alzheimers Dis 42 Suppl 3:S125-S152.
74. Matsuoka Y, Picciano M, La Francois J, Duff K (2001) Fibrillar beta-Amyloid evokes oxidative damage in a transgenic mouse model of Alzheimer's disease. Neuroscience 104:609-613.
75. Murakami K, Murata N, Noda Y, Tahara S, Kaneko T, Kinoshita N, Hatsuta H, Murayama S, Barnham KJ, Irie K, Shirasawa T, Shimizu T (2011) SOD1 (copper/zinc superoxide dismutase) deficiency drives amyloid beta protein oligomerization and memory loss in mouse model of Alzheimer disease. J Biol Chem 286:44557-44568.
76. Chen L, Na R, Gu M, Richardson A, Ran Q (2008) Lipid peroxidation up-regulates BACE1 expression in vivo: A possible early event of amyloidogenesis in Alzheimer's disease. J Neurochem 107:197-207.
77. Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM (2002) Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol 156:1051-1063.
78. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53:337-351.
79. David DC, Hauptmann S, Scherping I, Schuessel K, Keil U, Rizzu P, Ravid R, Dröse S, Brandt U, Möller WE, Eckert A, Götz J (2005) Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. J Biol Chem 280:23802-23814.
80. Halverson RA, Lewis J, Frausto S, Hutton M, Muma NA (2005) Tau protein is cross-linked by transglutaminase in P301L tau transgenic mice. J Neurosci 25:1226-1233.
81. Picone P, Nuzzo D, Caruana L, Scafidi V, Di Carlo M (2014) Mitochondrial dysfunction: different routes to Alzheimer's disease therapy. Oxid Med Cell Longev 2014:780179.
82. Castellani R, Hirai K, Aliev G, Drew KL, Nunomura A, Takeda A, Cash AD, Obrenovich ME, Perry G, Smith MA (2002) Role of mitochondrial dysfunction in Alzheimer's disease. J Neurosci Res 70:357-360.
83. Bubber P, Haroutunian V, Fisch G, Blass JP, Gibson GE (2005) Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann Neurol 57:695-703.
84. Ito E, Oka K, Etcheberrigaray R, Nelson TJ, McPhie DL, Tofel-Grehl B, Gibson GE, Alkon DL (1994) Internal Ca2+ mobilization is altered in fibroblasts from patients with Alzheimer disease. Proc Natl Acad Sci U S A 91:534-538.
85. Moon HE, Paek SH (2015) Mitochondrial Dysfunction in Parkinson's Disease. Exp Neurobiol 24:103-116.
86. Blesa J, Trigo-Damas I, Quiroga-Varela A, Jackson-Lewis VR (2015) Oxidative stress and Parkinson's disease. Front Neuroanat 9:91.
87. Schapira AH (2008) Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol 7:97-109.
88. Franco-Iborra S, Vila M, Perier C (2015) The Parkinson disease mitochondrial hypothesis: where are we at? Neuroscientist (in press).
89. Hauser DN, Hastings TG (2013) Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism. Neurobiol Dis 51:35-42.
90. Swerdlow RH, Parks JK, Miller SW, Tuttle JB, Trimmer PA, Sheehan JP, Bennett JP Jr, Davis RE, Parker WD Jr (1996) Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 40:663-671.
91. Bandmann O, Sweeney MG, Daniel SE, Marsden CD, Wood NW (1997) Mitochondrial DNA polymorphisms in pathologically proven Parkinson's disease. J Neurol 244:262-265.
92. Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marsden CD (1994) Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36:348-355.
93. Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 52:1830-1836.
94. Oakley AE, Collingwood JF, Dobson J, Love G, Perrott HR, Edwardson JA, Elstner M, Morris CM (2007) Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology 68:1820-1825.
95. Lovell MA, Ehmann WD, Butler SM, Markesbery WR (1995) Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 45:1594-1601.
96. Lovell MA, Xie C, Markesbery WR (1998) Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease. Neurology 51:1562-1566.
97. Rinaldi P, Polidori MC, Metastasio A, Mariani E, Mattioli P, Cherubini A, Catani M, Cecchetti R, Senin U, Mecocci P (2003) Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol Aging 24:915-919.
98. Sinclair AJ, Bayer AJ, Johnston J, Warner C, Maxwell SR (1998) Altered plasma antioxidant status in subjects with Alzheimer's disease and vascular dementia. Int J Geriatr Psychiatry 13:840-845.
99. McCaddon A, Hudson P, Hill D, Barber J, Lloyd A, Davies G, Regland B (2003) Alzheimer's disease and total plasma aminothiols. Biol Psychiatry 53:254-260.
100. Kalra J, Rajput AH, Mantha SV, Prasad K (1992) Serum antioxidant enzyme activity in Parkinson's disease. Mol Cell Biochem 110:165-168.
101. Ilic TV, Jovanovic M, Jovicic A, Tomovic M (1999) Oxidative stress indicators are elevated in de novo Parkinson's disease patients. Funct Neurol 14:141-147.
102. Kocatörk PA, Akbostanci MC, Tan F, Kavas GO (2000) Superoxide dismutase activity and zinc and copper concentrations in Parkinson's disease. Pathophysiology 7:63-67.
103. Serra JA, Domínguez RO, de Lustig ES, Guareschi EM, Famulari AL, Bartolomé EL, Marschoff ER (2001) Parkinson's disease is associated with oxidative stress: comparison of peripheral antioxidant profiles in living Parkinson's, Alzheimer's and vascular dementia patients. J Neural Transm 108:1135-1148.
104. Younes-Mhenni S, Frih-Ayed M, Kerkeni A, Bost M, Chazot G (2007) Peripheral blood markers of oxidative stress in Parkinson's disease. Eur Neurol 58:78-83.
105. Matsuzawa D, Hashimoto K (2011) Magnetic resonance spectroscopy study of the antioxidant defense system in schizophrenia. Antioxid Redox Signal 15:2057-2065.
106. Govindaraju V, Young K, Maudsley AA (2000) Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed 13:129-153.
107. Terpstra M, Henry PG, Gruetter R (2003) Measurement of reduced glutathione (GSH) in human brain using LCModel analysis of difference-edited spectra. Magn Reson Med 50:19-23.
108. Mandal PK, Tripathi M, Sugunan S (2012) Brain oxidative stress: detection and mapping of anti-oxidant marker 'Glutathione' in different brain regions of healthy male/ female, MCI and Alzheimer patients using non-invasive magnetic resonance spectroscopy. Biochem Biophys Res Commun 417:43-48.
109. Terpstra M, Gruetter R (2004) 1H NMR detection of vitamin C in human brain in vivo. Magn Reson Med 51:225-229.
110. Mandal PK, Saharan S, Tripathi M, Murari G (2015) Brain glutathione levels-a novel biomarker for mild cognitive impairment and Alzheimer's Disease. Biol Psychiatry (in press).
111. Shih YY, Böchert M, Chung HW, Hennig J, von Elverfeldt D (2008) Vitamin C estimation with standard (1)H spectroscopy using a clinical 3T MR system: detectability and reliability within the human brain. J Magn Reson Imaging 28:351-358.
112. Ikawa M, Okazawa H, Tsujikawa T, Matsunaga A, Yamamura O, Mori T, Hamano T, Kiyono Y, Nakamoto Y, Yoneda M (2015) Increased oxidative stress is related to disease severity in the ALS motor cortex: A PET study. Neurology 84:2033-2039.
113. Ikawa M, Okazawa H, Kudo T, Kuriyama M, Fujibayashi Y, Yoneda M (2011) Evaluation of striatal oxidative stress in patients with Parkinson's disease using [62Cu]ATSM PET. Nucl Med Biol 38:945-951.
114. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A (1997) Copper-62-ATSM: A new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 38:1155-1160.
115. Obata A, Yoshimi E, Waki A, Lewis JS, Oyama N, Welch MJ, Saji H, Yonekura Y, Fujibayashi Y (2001) Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells. Ann Nucl Med 15:499-504.
116. Hawkins CL, Davies MJ (2014) Detection and characterisation of radicals in biological materials using EPR methodology. Biochim Biophys Acta 1840:708-721.
117. Lee MC (2013) Assessment of oxidative stress and antioxidant property using electron spin resonance (ESR) spectroscopy. J Clin Biochem Nutr 52:1-8.
118. Mrakic-Sposta S, Gussoni M, Montorsi M, Porcelli S, Vezzoli A (2012) Assessment of a standardized ROS production profile in humans by electron paramagnetic resonance. Oxid Med Cell Longev 2012:973927.
119. Ienco EC, LoGerfo A, Carlesi C, Orsucci D, Ricci G, Mancuso M, Siciliano G (2011) Oxidative stress treatment for clinical trials in neurodegenerative diseases. J Alzheimers Dis 24 Suppl 2:111-126.
120. Saso L, Firuzi O (2014) Pharmacological applications of antioxidants: lights and shadows. Curr Drug Targets 15:1177-1199.
121. Morris MC, Beckett LA, Scherr PA, Hebert LE, Bennett DA, Field TS, Evans DA (1998) Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. Alzheimer Dis Assoc Disord 12:121-126.
122. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Aggarwal N, Wilson RS, Scherr PA (2002) Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA 287:3230-3237.
123. Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, Norton MC, Welsh-Bohmer KA, Breitner JC; Cache County Study Group (2004) Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: The Cache County Study. Arch Neurol 61:82-88.
124. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ (1997) A controlled trial of selegiline, alpha-Tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 336:1216-1222.
125. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ; Alzheimer's Disease Cooperative Study Group (2005) Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352: 2379-2388.
126. Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, Love S, Schellenberg GD, McCarten JR, Malphurs J, Prieto S, Chen P, Loreck DJ, Trapp G, Bakshi RS, Mintzer JE, Heidebrink JL, Vidal-Cardona A, Arroyo LM, Cruz AR, Zachariah S, Kowall NW, Chopra MP, Craft S, Thielke S, Turvey CL, Woodman C, Monnell KA, Gordon K, Tomaska J, Segal Y, Peduzzi PN, Guarino PD (2014) Effect of vitamin E and memantine on functional decline in Alzheimer disease: The TEAM-AD VA cooperative randomized trial. JAMA 311:33-44.
127. Galasko DR, Peskind E, Clark CM, Quinn JF, Ringman JM, Jicha GA, Cotman C, Cottrell B, Montine TJ, Thomas RG, Aisen P; Alzheimer's Disease Cooperative Study (2012) Antioxidants for Alzheimer disease: A randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol 69:836-841.
128. Adair JC, Knoefel JE, Morgan N (2001) Controlled trial of N-Acetylcysteine for patients with probable Alzheimer's disease. Neurology 57:1515-1517.
129. Bergamasco B, Scarzella L, La Commare P (1994) Idebenone, a new drug in the treatment of cognitive impairment in patients with dementia of the Alzheimer type. Funct Neurol 9: 161-168.
130. Weyer G, Babej-Dölle RM, Hadler D, Hofmann S, Herrmann WM (1997) A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease. Neuropsychobiology 36:73-82.
131. Gutzmann H, Hadler D (1998) Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study. J Neural Transm Suppl 54:301-310.
132. Thal LJ, Grundman M, Berg J, Ernstrom K, Margolin R, Pfeiffer E, Weiner MF, Zamrini E, Thomas RG (2003) Idebenone treatment fails to slow cognitive decline in Alzheimer's disease. Neurology 61:1498-1502.
133. Zhang SM, Hernán MA, Chen H, Spiegelman D, Willett WC, Ascherio A (2002) Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology 59:1161-1169.
134. Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328:176-183.
135. Shoulson I (1989) Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP). Parkinson Study Group. Acta Neurol Scand Suppl 126:171-175.
136. Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M; Parkinson Study Group (2002) Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 59:1541-1550.
137. Parkinson Study Group QE3 Investigators, Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, Voss TS, Ravina B, Shults CM, Helles K, Snively V, Lew MF, Griebner B, Watts A, Gao S, Pourcher E, Bond L, Kompoliti K, Agarwal P, Sia C, Jog M, Cole L, Sultana M, Kurlan R, Richard I, Deeley C, Waters CH, Figueroa A, Arkun A, Brodsky M, Ondo WG, Hunter CB, Jimenez-Shahed J, Palao A, Miyasaki JM, So J, Tetrud J, Reys L, Smith K, Singer C, Blenke A, Russell DS, Cotto C, Friedman JH, Lannon M, Zhang L, Drasby E, Kumar R, Subramanian T, Ford DS, Grimes DA, Cote D, Conway J, Siderowf AD, Evatt ML, Sommerfeld B, Lieberman AN, Okun MS, Rodriguez RL, Merritt S, Swartz CL, Martin WR, King P, Stover N, Guthrie S, Watts RL, Ahmed A, Fernandez HH, Winters A, Mari Z, Dawson TM, Dunlop B, Feigin AS, Shannon B, Nirenberg MJ, Ogg M, Ellias SA, Thomas CA, Frei K, Bodis-Wollner I, Glazman S, Mayer T, Hauser RA, Pahwa R, Langhammer A, Ranawaya R, Derwent L, Sethi KD, Farrow B, Prakash R, Litvan I, Robinson A, Sahay A, Gartner M, Hinson VK, Markind S, Pelikan M, Perlmutter JS, Hartlein J, Molho E, Evans S, Adler CH, Duffy A, Lind M, Elmer L, Davis K, Spears J, Wilson S, Leehey MA, Hermanowicz N, Niswonger S, Shill HA, Obradov S, Rajput A, Cowper M, Lessig S, Song D, Fontaine D, Zadikoff C, Williams K, Blindauer KA, Bergholte J, Propsom CS, Stacy MA, Field J, Mihaila D, Chilton M, Uc EY, Sieren J, Simon DK, Kraics L, Silver A, Boyd JT, Hamill RW, Ingvoldstad C, Young J, Thomas K, Kostyk SK, Wojcieszek J, Pfeiffer RF, Panisset M, Beland M, Reich SG, Cines M, Zappala N, Rivest J, Zweig R, Lumina LP, Hilliard CL, Grill S, Kellermann M, Tuite P, Rolandelli S, Kang UJ, Young J, Rao J, Cook MM, Severt L, Boyar K (2014) A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol 71:543-552.
138. Murphy MP (2014) Antioxidants as therapies: can we improve on nature? Free Radic Biol Med 66:20-23.
139. Firuzi O, Miri R, Tavakkoli M, Saso L (2011) Antioxidant therapy: current status and future prospects. Curr Med Chem 18:3871-3888.
140. Praticò D (2008) Evidence of oxidative stress in Alzheimer's disease brain and antioxidant therapy: lights and shadows. Ann N Y Acad Sci 1147:70-78.